Alnylam Pharmaceuticals Inc (ALNY)
150.31
+0.35
(+0.23%)
USD |
NASDAQ |
May 02, 16:00
150.14
-0.17
(-0.11%)
After-Hours: 20:00
Alnylam Pharmaceuticals Revenue (Annual): 1.828B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.828B |
| December 31, 2022 | 1.037B |
| December 31, 2021 | 844.29M |
| December 31, 2020 | 492.85M |
| December 31, 2019 | 219.75M |
| December 31, 2018 | 74.91M |
| December 31, 2017 | 89.91M |
| December 31, 2016 | 47.16M |
| December 31, 2015 | 41.10M |
| December 31, 2014 | 50.56M |
| December 31, 2013 | 47.17M |
| Date | Value |
|---|---|
| December 31, 2012 | 66.72M |
| December 31, 2011 | 82.76M |
| December 31, 2010 | 100.04M |
| December 31, 2009 | 100.53M |
| December 31, 2008 | 96.16M |
| December 31, 2007 | 50.90M |
| December 31, 2006 | 26.93M |
| December 31, 2005 | 5.716M |
| December 31, 2004 | 4.278M |
| December 31, 2003 | 0.176M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
219.75M
Minimum
2019
1.828B
Maximum
2023
884.52M
Average
844.29M
Median
2021
Revenue (Annual) Benchmarks
| Ionis Pharmaceuticals Inc | 787.65M |
| Pfizer Inc | 58.50B |
| Blueprint Medicines Corp | 249.38M |
| Madrigal Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 1.243B |